Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

May 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

May 2025 Dispatch for the CV Team

May 20, 2025

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

News Daily News

Rethinking the Evidence for ICDs for HFrEF in Light of Today’s GDMT

December 05, 2024

July 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

July 01, 2024

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

ICD Benefits Hold Up for Modern-day Primary Prevention, but Questions Remain

News Daily News

ICD Benefits Hold Up for Modern-day Primary Prevention, but Questions Remain

March 25, 2024

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

October 2023 News Roundup

News Opinion CV Team Dispatch

October 2023 News Roundup

October 01, 2023

PCI Doesn’t Cut Arrhythmias in Severe LV Dysfunction: REVIVED-BCIS2 Analysis

News Daily News

PCI Doesn’t Cut Arrhythmias in Severe LV Dysfunction: REVIVED-BCIS2 Analysis

August 14, 2023

August 2023 News Roundup

News Opinion CV Team Dispatch

August 2023 News Roundup

August 01, 2023

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

News Conference News HFSA 2022

New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented

October 07, 2022

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

May 02, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

December 2021 News Roundup

News Opinion CV Team Dispatch

December 2021 News Roundup

December 01, 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

News Conference News ESC Heart Failure 2021

Beta-blocker Withdrawal Boosts Peak VO2 in HFpEF Subset: PRESERVE-HR

July 06, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.